Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Bekaii-Saab Highlights Targeted Therapy Advances in CRC

June 2nd 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses the growing role of targeted therapy in CRC.

Trastuzumab Deruxtecan Shows Promising Clinical Activity in CRC and Gastric/GEJ Tumors

May 31st 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors

May 30th 2020

AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer and colorectal cancer.

Dr. Kopetz on Updated Data From BEACON CRC Study in BRAF V600E-Mutant CRC

May 30th 2020

Scott Kopetz, MD, PhD, FACP, discusses the updated survival data from the BEACON CRC study in BRAF V600E–mutated metastatic colorectal cancer.

Pembrolizumab Doubles PFS in Newly Diagnosed MSI-H/dMMR mCRC

May 29th 2020

Pembrolizumab doubled progression-free survival compared with chemotherapy in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer, according to findings from an interim analysis of the phase 3 KEYNOTE-177 trial.

FDA Grants Onvansertib Fast Track Designation in KRAS+ mCRC

May 28th 2020

The FDA has granted Fast Track designation to onvansertib for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

Dr. Mizrahi on Targeting Treatment in Metastatic Colorectal Cancer

May 28th 2020

Jonathan Mizrahi, MD, discusses efforts being made to target treatment for patients with metastatic colorectal cancer.

Dr. Le on Research Needed to Address Unmet Needs in mCRC

May 27th 2020

Phat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.

Dr. Raghav on the Utility of ctDNA in CRC

May 27th 2020

Kanwal Raghav, MBBS, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Dr. Nelson on Why Patients With mCRC are Often Referred to Surgeons First

May 22nd 2020

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

May 20th 2020

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Multimodal Blood Test Successfully Screens for Advanced CRC, Adenomas

May 8th 2020

Shai Friedland, MD, discusses the importance of screening for colorectal cancer, the advantages of the noninvasive FirstSightCRC blood test, and the results from the ZENITH trial.

Onvansertib Regimen Shows Early Promise in KRAS-Mutant mCRC

May 7th 2020

Heinz-Josef Lenz, MD, FACP, discusses the next steps for the trial examining the onvansertib combination and sheds light on the possibility of this regimen eventually being used in the frontline setting.

Dr. Overman on Ongoing Research With Immunotherapy in Microsatellite Stable CRC

May 6th 2020

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Nivolumab Plus Regorafenib Regimen Active in Gastrointestinal Cancers

May 5th 2020

The combination of nivolumab and regorafenib demonstrated promising antitumor activity in patients with gastric and colorectal cancer.

Dr. Bekaii-Saab on Moving Metastatic Treatment Strategies to the Adjuvant Setting in CRC

May 2nd 2020

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

Encorafenib/Cetuximab Combo Nears EU Approval for BRAF+ mCRC

May 1st 2020

A European panel has recommended approval of encorafenib in combination with cetuximab for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer.

FDA Approves Encorafenib/Cetuximab Combo for BRAF+ mCRC

April 9th 2020

The FDA has approved the combination of encorafenib and cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation, following prior therapy.

Pembrolizumab Improves PFS in Frontline MSI-H/dMMR Colorectal Cancer

April 2nd 2020

Frontline pembrolizumab significantly improved progression-free survival versus chemotherapy in patients with microsatellite instability–high or mismatch repair deficient unresectable or metastatic colorectal cancer.

Dr. Raghav on Ongoing Research With Immunotherapy and Targeted Therapy in CRC

April 2nd 2020

Kanwal Raghav, MBBS, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy and targeted therapy in colorectal cancer (CRC).